News
IMMX
8.74
+3.19%
0.27
Weekly Report: what happened at IMMX last week (0608-0612)?
Weekly Report · 1d ago
Weekly Report: what happened at IMMX last week (0601-0605)?
Weekly Report · 06/08 10:32
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
Seeking Alpha · 06/02 14:20
Weekly Report: what happened at IMMX last week (0525-0529)?
Weekly Report · 06/01 10:38
Immix Biopharma Shareholders Back Board and Auditor at AGM
TipRanks · 05/29 22:28
Immix Biopharma shareholders elect directors at annual meeting
PUBT · 05/29 21:10
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
TipRanks · 05/26 23:50
Weekly Report: what happened at IMMX last week (0518-0522)?
Weekly Report · 05/25 10:41
Immix Biopharma closes $150 million common stock offering at $8.94 per share
PUBT · 05/22 21:15
IMMIX BIOPHARMA ANNOUNCES CLOSING OF $150 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK
Reuters · 05/22 21:15
Immix Biopharma Price Target Raised to $20.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 05/22 16:14
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/22 16:14
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $20
Benzinga · 05/22 16:04
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
TipRanks · 05/22 14:41
IMMIX BIOPHARMA, INC. <IMMX.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $20 FROM $15
Reuters · 05/22 14:38
U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday
Reuters · 05/22 06:49
Immix Biopharma Raises $150 Million to Advance NXC-201
TipRanks · 05/21 23:57
What's Going On With Immix Biopharma Stock Thursday?
Benzinga · 05/21 17:16
Immix Biopharma Prices $150 Million Underwritten Offering To Advance NXC-201 Program
NASDAQ · 05/21 12:21
Immix Biopharma prices $150M stock offering at $8.94/share
Seeking Alpha · 05/21 11:53
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.